C92.02 Acute myeloblastic leukemia, in relapse

Name of the Condition

• Acute Myeloblastic Leukemia, in Relapse

Summary

Acute myeloblastic leukemia (AML) is a cancer of the bone marrow that results in the rapid growth of abnormal myeloblasts, a type of immature white blood cell. This uncontrolled proliferation disrupts normal blood cell production, leading to deficiencies in red blood cells, platelets, and functional white blood cells. When in relapse, the disease indicates a return of active leukemia after a period of remission, with renewed abnormal cell production and clinical manifestations.

Causes

AML arises from genetic mutations in hematopoietic stem cells, which disrupt normal cell differentiation and promote uncontrolled proliferation. These mutations may occur spontaneously or be acquired. Common mutations involve genes such as FLT3, NPM1, and RUNX1, which affect cell growth and survival pathways. Relapse occurs when residual leukemic cells, potentially harboring persistent genetic abnormalities, reemerge and proliferate despite prior treatment.

Risk Factors

• Age: Primarily affects older adults, with incidence increasing after age 60.
• Previous chemotherapy or radiation therapy for other cancers.
• Exposure to high levels of benzene or other industrial chemicals.
• Genetic disorders, including Down syndrome and Fanconi anemia.
• Myelodysplastic syndromes or other pre-existing bone marrow diseases.

Symptoms

• Fatigue, weakness, or shortness of breath due to anemia.
• Easy bruising, bleeding, or petechiae from low platelet counts.
• Frequent or severe infections due to neutropenia.
• Unexplained fever or weight loss.
• Bone or joint pain.

Diagnosis

Diagnosis involves a combination of clinical evaluation, laboratory tests, and imaging. A complete blood count (CBC) typically shows abnormal cell counts. Bone marrow aspiration and biopsy confirm the presence of leukemic blasts and assess their morphology. Cytogenetic and molecular testing identify specific genetic mutations. Additional tests, such as lumbar puncture, may evaluate central nervous system involvement.

Treatment Options

Treatment focuses on inducing remission and preventing further relapse. Induction chemotherapy targets rapidly dividing leukemic cells. Consolidation therapy follows to eliminate residual disease. Options may include targeted therapies, stem cell transplantation, or clinical trials, depending on the patient’s age, health, and genetic profile. Supportive care manages symptoms and complications.

Prognosis and Follow-Up

Prognosis depends on factors like age, genetic mutations, and response to initial treatment. Relapse generally indicates a more aggressive disease course and may require alternative therapies. Regular follow-up includes blood tests, bone marrow evaluations, and monitoring for recurrence. Long-term surveillance is essential to detect late effects or secondary malignancies.

Complications

• Infection due to neutropenia or impaired immune function.
• Bleeding or hemorrhage from low platelet counts.
• Anemia leading to fatigue or organ dysfunction.
• Tumor lysis syndrome from rapid cell breakdown.
• Resistance to treatment or progression to more aggressive disease.

Lifestyle & Prevention

• Avoid exposure to known carcinogens, such as benzene.
• Maintain a balanced diet and regular exercise to support overall health.
• Follow recommended cancer screening guidelines, especially for high-risk individuals.
• Adhere to prescribed treatments and attend all follow-up appointments.

When to Seek Professional Help

Seek immediate medical attention for symptoms like unexplained fever, severe bleeding, or sudden fatigue. Contact a healthcare provider if you experience persistent or worsening signs of infection, bruising, or shortness of breath. Regular check-ups are critical for those with a history of AML or relapse.

Tips for Medical Coders

Document the presence of relapse clearly in the medical record, including clinical or hematologic evidence of active disease. Ensure coding aligns with the specific phase of AML (e.g., relapse) and any associated treatments. Verify that documentation supports the diagnosis and excludes other conditions with similar presentations.